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Abstract
Aims/hypothesis Depression is twice as common in individuals with type 2 diabetes as in the general population. However, it
remains unclear whether hyperglycaemia and insulin resistance are directly involved in the aetiology of depression. Therefore,
we investigated the association of markers of hyperglycaemia and insulin resistance, measured as continuous variables, with
incident depressive symptoms over 4 years of follow-up.
Methods We used data from the longitudinal population-based Maastricht Study (n = 2848; mean age 59.9 ± 8.1 years, 48.8%
women, 265 incident depression cases, 10,932 person-years of follow-up). We assessed hyperglycaemia by fasting and 2 h post-
load OGTT glucose levels, HbA1c and skin autofluorescence (reflecting AGEs) at baseline. We used the Matsuda insulin
sensitivity index and HOMA-IR to calculate insulin resistance at baseline. Depressive symptoms (nine-item Patient Health
Questionnaire score ≥10) were assessed at baseline and annually over 4 years. We used Cox regression analyses, and adjusted
for demographic, cardiovascular and lifestyle risk factors.
Results Fasting plasma glucose, 2 h post-load glucose and HbA1c levels were associated with an increased risk for incident
depressive symptoms after full adjustment (HR 1.20 [95%CI 1.08, 1.33]; HR 1.25 [1.08, 1.44]; and HR 1.22 [1.09, 1.37] per SD,
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respectively), while skin autofluorescence, insulin sensitivity index and HOMA-IR were not (HR 0.99 [0.86, 1.13]; HR 1.02
[0.85, 1.25]; and HR 0.93 [0.81, 1.08], per SD, respectively).
Conclusions/interpretation The observed temporal association between hyperglycaemia and incident depressive symptoms in
this study supports the presence of a mechanistic link between hyperglycaemia and the development of depressive symptoms.
Keywords Depression . Depressive symptoms . Epidemiology . Hyperglycaemia . Insulin resistance . Population-based cohort
study . Type 2 diabetesmellitus
Abbreviations
IGM Impaired glucose metabolism
ISI Insulin sensitivity index
MDD Major depressive disorder
NGM Normal glucose metabolism
PHQ-9 Nine-item Patient Health Questionnaire
ROS Reactive oxygen species
SAF Skin autofluorescence
Introduction
The prevalence of depression is nearly doubled in individuals
with type 2 diabetes as compared with the general population,
with prevalence rates of 6.5% to 33% [1]. Comorbid depres-
sion in type 2 diabetes is associated with impaired quality of
life [2], worse self-care, suboptimal blood glucose levels and
an increased risk for macro- and microvascular complications,
mortality [3] and dementia [4]. In addition, their co-
occurrence has an adverse economic impact with increased
healthcare costs and decreased work productivity [5].
Furthermore, depression appears to be highly persistent and/
or recurrent in type 2 diabetes [6]. Although there is evidence
for a bidirectional association between type 2 diabetes and
depression, the exact nature and the aetiological direction of
the relationship remain unknown [1].
Hyperglycaemia and insulin resistance are key features of
type 2 diabetes, and have been proposed as underlying mech-
anisms involved in the aetiology of depression [7]. Both fluc-
tuations in plasma glucose and prolonged hyperglycaemia
may be involved in the development of depression. The brain
is particularly vulnerable to fluctuations in plasma glucose
levels because neurons do not possess an active glucose trans-
porter. As a consequence, high extracellular glucose levels
lead to high intracellular glucose levels. The resulting
2316 Diabetologia (2020) 63:2315–2328
biochemical changes, for instance the formation of reactive
oxygen species (ROS) or AGEs, and accumulation of the
resulting damage over the years, may lead to neuronal damage
and/or disturbances of the hypothalamic–pituitary–adrenal
axis, which eventually may lead to depression [7]. However,
current evidence on the temporality of these associations
remains scarce. A recent meta-analysis of prospective studies
found an association between prevalent diabetes and incident
depression but not between impaired glucose metabolism
(IGM) or newly diagnosed type 2 diabetes and incident
depression, compared with normal glucose metabolism
(NGM) [8]. However, numbers for incident depression with
IGM [9–11] or newly diagnosed type 2 diabetes were relative-
ly small [10–13] and thus confidence intervals were large, and
all studies used categorical instead of continuous values of
glucose metabolism.
With regard to insulin resistance, only four prospective
studies examined the association with incident depression.
One study found an association [14], while the others did
not [15–17]. However, these studies have important method-
ological limitations, such as a single follow-up assessment of
depression [14, 16, 17], inclusion of only men [15] or only
elderly men [14], a small study population [17] or a small
number of incident depression cases [14].
In summary, there is a need for methodologically well-
conducted prospective studies to assess whether
hyperglycaemia and insulin resistance are temporally related
to the development of depression. Therefore, the aim of this
study was to examine the associations of markers of
hyperglycaemia and insulin resistance measured as continu-
ous variables with incident clinically relevant depressive
symptoms within the population-based Maastricht Study. In
addition, we assessed whether these associations were inde-
pendent of demographic, cardiovascular and lifestyle risk
factors, or differed between women and men. We
hypothesised that hyperglycaemia and higher levels of insulin
resistance are independently associated with incident clinical-
ly relevant depressive symptoms, and that these associations
are similar in women and men.
Methods
Study population and design The Maastricht Study is an
observational population-based cohort study. The rationale
and methodology have been described previously [18]. In
brief, the study focuses on the aetiology, pathophysiology,
complications and comorbidities of type 2 diabetes and is
characterised by an extensive phenotyping approach.
Eligible for participation were all individuals aged between
40 and 75 years and living in the southern part of the
Netherlands. Participants were recruited through mass media
campaigns, the municipal registries and the regional Diabetes
Patient Registry via mailings. Recruitment was stratified
according to known type 2 diabetes status, with an
oversampling of individuals with type 2 diabetes, for reasons
of efficiency. The present report includes baseline data from
3124 participants, who completed the baseline survey
between November 2010 and September 2013. Figure 1 gives
an overview of the study design. The baseline examinations of
each participant were performed within a time window of
3 months. Follow-up data were only available for depression
data and were available in 91.9%, 85.4%, 79.9% and 71.4% of
the participants with available baseline data at, respectively, 1,
2, 3 and 4 years of follow-up. The study has been approved by
the institutional medical ethical committee (NL31329.068.10)
and the Minister of Health, Welfare, and Sports of the
Netherlands (Permit 131088-105234-PG). All participants
gave written informed consent.
Figure 2 shows the flowchart of the study population. From
the initial 3451 participants we excluded individuals with
other types of diabetes than type 2 diabetes (n = 41). For the
cross-sectional analyses we included participants with avail-
able hyperglycaemia, insulin resistance and nine-item Patient
Health Questionnaire (PHQ-9) data at baseline (n = 3124). For
the longitudinal analyses, we excluded participants with clin-
ically relevant depressive symptoms at baseline (PHQ-9 score
≥10, n = 139) or without any follow-up PHQ-9 data (n = 137)
to investigate the associations with newly developed depres-
sive symptoms during follow-up, resulting in a study popula-
tion of 2848 participants with an average follow-up duration
of 3.8 ± 1.0 years.
Hyperglycaemia Markers of hyperglycaemia were measured
at baseline. Participants, except those who used insulin (as
endogenous insulin production is limited), underwent a
standardised 2 h 75 g OGTT to determine fasting and 2 h
post-load blood glucose levels after an overnight fast. For
safety reasons, participants with a fasting glucose level above
11.0 mmol/l, as determined by a finger prick, did not undergo
the OGTT (n = 42). Venous fasting and 2 h post-load plasma
glucose levels were measured by the enzymatic hexokinase
method on two automatic analysers, the Beckman Synchron
LX20 (Beckman Coulter, CA, USA) for samples obtained
between November 2010 and April 2012, and the Roche
Cobas 6000 (Roche Diagnostics, Mannheim, Germany) for
samples obtained thereafter. Glucose metabolism status was
defined according to the World Health Organization 2006
criteria as NGM, prediabetes (fasting glucose 6.1–7.0 mmol/l
or 2 h post-load blood glucose 7.8–11.1 mmol/l) or type 2
diabetes (fasting blood glucose ≥7.0 mmol/l or 2 h post-load
blood glucose ≥11.1 mmol/l, or used oral glucose-lowering
medication or insulin) [19]. Type 1 diabetes and other types
of diabetes were determined by use of a clinical interview.
HbA1c was determined in fasting venous blood samples by
ion-exchange high performance liquid chromatography [18].
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Skin autofluorescence (SAF) was measured with the AGE
Reader (DiagnOptics Technologies, Groningen, the
Netherlands), which is a desktop device that uses ultraviolet
light to excite autofluorescence in human skin tissue to esti-
mate the level of AGE accumulation in the skin, as described
elsewhere [20].
Insulin resistance Insulin resistance was assessed by the
Matsuda insulin sensitivity index (ISI) and the HOMA-IR
[21] at baseline only. The ISI was calculated as suggested by
DeFronzo and Matsuda [22]: ISI = 10,000/(G0 × I0 ×Gmean ×
Imean)1/2, whereG and I represent plasma glucose (mmol dl
−1)
and insulin (mU l−1) concentrations, respectively, and ‘0’ and
‘mean’ indicate fasting value and mean value during OGTT,
The Maastricht Study population
(n=3451)
• Type 1 and other types of 
diabetes mellitus (n=41)
• Missing baseline PHQ-9 data 
(n=285)
• No available hyperglycaemia 
data (n=1)
Study population with available follow-up data
(n=2848)
• Fasting plasma glucose available in n=2846
• 2 h post-load glucose available in n=2683
• HbA1c available in n=2842
• SAF available in n=2710
• ISI in n=2496
• HOMA-IR available in n=2585
Study population with full available follow-up data
(n=2716)
• Fasting plasma glucose available in n=2714
• 2 h post-load glucose available in n=2565
• HbA1c available in n=2710
• SAF available in n=2582
• ISI available in n=2400
• HOMA-IR available in n=2488
Missing on covariate
a
• Education level (n=49)
• Waist circumference (n=3)





• Lipid-modifying medication 
(n=3)
• eGFR (n=26)
• History of CVD (n=71)
• Smoking behaviour (n=39)
• Alcohol use (n=43)
Study population with available baseline data 
(n=3124)
• Fasting plasma glucose available in n=3121
• 2 h post-load glucose available in n=2920
• HbA1c available in n=3115
• SAF available in n=2959
• ISI available in n=2709
• HOMA-IR available in n=2814
• Baseline PHQ-9≥10 (n=139)
• No available PHQ-9 follow-up 
data (n=137)
Fig. 2 Flowchart of study
population. aMissing data on
covariates are not mutually
exclusive
Measurements:
• Fasting plasma 
glucose 

















1 year follow upBaseline 2 year follow up 3 year follow up
Fig. 1 Study design
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respectively. The reciprocal (i.e. 1/ISI) was used to reflect
insulin resistance as a risk factor. The ISI is strongly correlated
(r = 0.73, p < 0.0001) with the rate of whole-body glucose
disposal during the euglycaemic insulin clamp [23].
HOMA-IR was calculated with the HOMA2 calculator
version 2.2.3 forWindows [24]. HOMA-IR is the most widely
used and validated surrogate marker of insulin resistance and
corresponds reasonably well to clamp-derived measures of
insulin sensitivity [25]. Neither measure was calculated for
participants receiving insulin treatment (n = 169); as endoge-
nous insulin levels will be close to zero, ISI and HOMA-IR
calculations will result in zero as well.
Depressive symptoms Depressive symptoms were assessed
by a validated Dutch version of the PHQ-9 [26] both at base-
line and during annual follow-up over 4 years. The PHQ-9 is a
self-administered questionnaire that assesses the presence of
the nine symptoms for the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) criteria for a major depressive
disorder (MDD) [27] on a four-point Likert-scale ranging
from 0, ‘not at all’, to 4, ‘nearly every day’. When one or
two items were missing, the total score was calculated as
9 × (total points/9 − number of missing items) and rounded
to the nearest integer. When more items were missing, the
total score was scored as missing.
A cut-off score of ≥10 is most often used as a dichotomous
scoring system for defining clinically relevant depressive
symptoms, with sensitivity and specificity of, respectively,
88% and 78% [28]. Online PHQ-9 questionnaires were
completed annually during a follow-up period of 4 years.
Prevalent depressive symptoms were defined as clinically
relevant depressive symptoms at baseline (PHQ-9 ≥10).
Incident depressive symptoms were defined as no depressive
symptoms at baseline (PHQ-9 <10) and presence of clinically
relevant depressive symptoms on at least one follow-up
moment (PHQ-9 ≥10). In addition, at baseline only, current
and lifetime diagnosis of MDD was assessed by the Mini-
International Neuropsychiatric Interview (MINI) [29].
General characteristics and covariates General characteristics
and covariates were measured at baseline. Educational level
(low, intermediate, high), partner status (partner/no partner),
history of CVD, smoking status (never, current, former), alco-
hol consumption (none, low, high), physical activity and
Mediterranean diet score were assessed by questionnaires
[18].Wemeasured height, weight, waist circumference, office
blood pressure, plasma lipid profile, eGFR (in ml min−1
1.73 m−2) and 24 h urinary albumin excretion (twice).
Urinary albumin excretion was defined as normal (<15 mg/
24 h), microalbuminuria (15 to <30 mg/24 h) or
macroalbuminuria (≥30 mg/24 h). Medication use was
assessed in a medication interview where generic name, dose
and frequency were registered. More details about these
general characteristics and covariates are provided in the elec-
tronic supplementary material (ESM) methods.
Statistical analysis All statistical analyses were performed
by use of the Statistical Package for Social Sciences
(version 25.0; IBM, Chicago, Illinois, USA). General char-
acteristics of the study population were evaluated using
independent t tests, Mann–Whitney U tests or χ2 tests.
Negative binomial and logistic regression analyses were
used to investigate the cross-sectional associations of
markers of hyperglycaemia and insulin resistance per SD
with, respectively, depressive symptoms and clinically
relevant depressive symptoms. We used Cox proportional
regression analyses to assess the association of markers of
hyperglycaemia and insulin resistance per SD with inci-
dent depressive symptoms (PHQ-9 ≥10), with time-in-
study as time axis. Participants were censored at the date
of the event or, in case of attrition, the last available date
of follow-up, whichever came first. Hazard ratios indicate
the increased risk for incident depressive symptoms per
SD higher marker of hyperglycaemia or insulin resistance.
We performed complete case analyses in which associa-
tions were adjusted for potential confounders in four
models: model 1, crude; model 2, adjusted for demograph-
ic confounders (age, sex and educational level); model 3,
additionally adjusted for cardiovascular risk factors (waist
circumference, office systolic blood pressure, blood
pressure-lowering medication, total-to-HDL-cholesterol
ratio, lipid-modifying medication, eGFR and history of
CVD); and model 4, additionally adjusted for modifiable
lifestyle-related risk factors (smoking behaviour and alco-
hol use). We also investigated whether there was an inter-
action with sex in the fully adjusted model.
Several additional analyses were performed. To study
whether the associations were driven by the oversampling
of individuals with diagnosed type 2 diabetes, we addition-
ally adjusted for type 2 diabetes, and excluded participants
with type 2 diabetes from the analyses. To reduce potential
misclassification of participants with subthreshold depres-
sion (MDD but low PHQ-9 scores due to remission or
treatment), we performed the following sensitivity analyses;
first, we additionally adjusted for use of antidepressant
medication at baseline; second, we excluded participants
who used antidepressant medication at baseline; and third,
we excluded participants who had an MDD diagnosis at
baseline. To restrict analyses to ‘de novo’ depression, we
excluded participants who had a lifetime MDD diagnosis.
We also applied stricter rules on the follow-up data,
allowing no or a maximum of one missing follow-up
measurement. Furthermore, we additionally adjusted for
physical activity and Mediterranean diet score, as these data
were missing in more participants. Finally, we replaced
office systolic blood pressure with 24 h ambulatory systolic
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blood pressure, waist circumference with BMI and total-to-
HDL-cholesterol ratio with triacylglycerols. A two-sided p
value <0.05 was considered statistically significant.
Results
General characteristics of the study populationDuring 10,932
person-years of follow-up, 265 (9.3%) participants developed
clinically relevant depressive symptoms (PHQ-9 ≥10; average
Table 1 General characteristics and markers of hyperglycaemia and insulin resistance according to incident depression status








Age (years) 59.9 ± 8.1 59.8 ± 8.2 0.768
Sex, n (% female) 1263 (48.9) 127 (47.9) 0.796
Educational level, low/medium/high, n (%) 766/723/1048 (30.2/28.5/41.3) 114/79/69 (43.5/30.2/26.3) <0.001
Partner status, n (%) (partner) 2187 (85.8) 218 (82.9)
Depression
Depressive symptoms (PHQ-9 score) 2.0 ± 2.1 4.5 ± 2.8 <0.001
MDD (MINI), n (%) 23 (1.0) 18 (7.1) <0.001
Anti-depressive medication, n (%) 124 (4.8) 40 (15.1) <0.001
Cardiovascular risk factors
BMI (kg/m2) 26.7 ± 4.3 28.5 ± 5.2 <0.001
Waist circumference (cm) 94.7 ± 13.1 100.0 ± 15.2 <0.001
Office systolic BP (mmHg) 134.6 ± 17.9 135.6 ± 19.5 0.397
Office diastolic BP (mmHg) 76.1 ± 9.7 76.6 ± 11.2 0.480
Antihypertensive medication, n (%) 953 (37.0) 133 (50.2) <0.001
Hypertension, n (%) 1405 (54.5) 165 (62.3) 0.016
Total-to-HDL-cholesterol ratio 3.6 ± 1.1 3.9 ± 1.3 0.003
Triacylglycerols (mmol/l) 1.4 ± 0.8 1.7 ± 1.3 <0.001
Lipid-modifying medication, n (%) 860 (33.4) 109 (41.1) 0.012
eGFR (ml min−1 1.73 m−2) 88.3 ± 14.3 86.6 ± 16.6 0.124
Albuminuria, normal/micro/macro, n (%) 2238/157/15 (92.9/6.5/0.6) 214/29/4 (86.6/11.7/1.6) <0.001
History of CVD, n (%) 376 (15.0) 66 (25.4) <0.001
Type 2 diabetes mellitus, n (%) 612 (23.7) 110 (41.5) <0.001
Diabetes medication (all types), n (%) 456 (17.7) 92 (34.7) <0.001
Diabetes medication (insulin), n (%) 102 (3.9) 32 (12.1) <0.001
Lifestyle factors
Smoking, never/former/current, n (%) 929/1340/278 (36.5/52.6/10.9) 77/129/56 (29.4/49.2/21.4) <0.001
Alcohol use, none/low/high, n (%) 399/1443/702 (15.7/56.7/27.6) 68/144/49 (26.1/55.2/18.8) <0.001
Physical activity (h/week) 14.4 ± 8.0 13.0 ± 8.8 0.008
Mediterranean diet score 4.5 ± 1.7 4.2 ± 1.6 0.008
Markers of hyperglycaemia and insulin resistance
Fasting plasma glucose (mmol/l) 5.9 ± 1.4 6.6 ± 2.2 <0.001
2 h post-load glucose (mmol/l) 7.6 ± 4.0 8.9 ± 4.9 <0.001
HbA1c (mmol/mol) 39.9 ± 8.5 44.4 ± 11.5 <0.001
HbA1c (%) 5.8 ± 0.8 6.2 ± 1.1 <0.001
SAF (AU) 2.4 ± 0.5 2.5 ± 0.6 0.010
HOMA-IR 1.7 ± 1.1 1.9 ± 1.2 0.021
ISI 4.1 ± 2.7 3.6 ± 2.4 0.008
Data are presented as mean±SD or number and percentage, as appropriate
AU, arbitrary units
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follow-up time of 2.5 ± 1.2 years), which yields an inci-
dence rate of 24 cases per 1000 person-years.
Participants not included in the analyses (n = 603) were
statistically significantly younger, had a lower level of
education, less often had a partner, had higher levels of
hyperglycaemia and insulin resistance, and had a worse
Table 2 Cross-sectional associations of markers of hyperglycaemia and insulin resistance with prevalent depressive symptoms
Model Prevalent depressive
symptoms
Rate ratio (95% CI)
p value Prevalent clinically relevant




Fasting plasma glucose (per 1 SD)
Model 1 1.08 (1.04, 1.12) <0.001 1.30 (1.15, 1.46) <0.001
Model 2 1.15 (1.10, 1.20) <0.001 1.41 (1.25, 1.60) <0.001
Model 3 1.08 (1.03, 1.13) 0.001 1.17 (1.00, 1.36) 0.045
Model 4 1.07 (1.02, 1.12) 0.008 1.13 (0.97, 1.32) 0.130
2 h post-load glucose (per 1 SD)
Model 1 1.04 (1.00, 1.08) 0.074 1.19 (1.01, 1.41) 0.042
Model 2 1.10 (1.05, 1.15) <0.001 1.35 (1.13, 1.61) 0.001
Model 3 1.03 (0.98, 1.09) 0.298 1.06 (0.84, 1.33) 0.619
Model 4 1.02 (0.97, 1.08) 0.407 1.05 (0.84, 1.33) 0.656
HbA1c (per 1 SD)
Model 1 1.12 (1.07, 1.16) <0.001 1.42 (1.26, 1.61) <0.001
Model 2 1.18 (1.13, 1.23) <0.001 1.54 (1.35, 1.75) <0.001
Model 3 1.11 (1.06, 1.16) <0.001 1.30 (1.11, 1.52) 0.001
Model 4 1.08 (1.03, 1.13) 0.002 1.21 (1.03, 1.42) 0.022
SAF (per 1 SD)
Model 1 1.03 (0.99, 1.08) 0.122 1.18 (1.00, 1.39) 0.051
Model 2 1.11 (1.06, 1.16) <0.001 1.43 (1.19, 1.72) <0.001
Model 3 1.07 (1.02, 1.13) 0.004 1.31 (1.07, 1.60) 0.009
Model 4 1.04 (0.99, 1.09) 0.152 1.18 (0.95, 1.45) 0.129
Markers of insulin resistance
ISI (per SD)a
Model 1 1.04 (1.00, 1.09) 0.056 1.16 (0.93, 1.45) 0.182
Model 2 1.10 (1.05, 1.15) <0.001 1.29 (1.02, 1.63) 0.033
Model 3 1.02 (0.96, 1.07) 0.598 0.89 (0.69, 1.15) 0.363
Model 4 1.01 (0.96, 1.07) 0.621 0.88 (0.68, 1.14) 0.323
HOMA-IR (per SD)
Model 1 1.07 (1.02, 1.12) 0.004 1.20 (1.02, 1.42) 0.032
Model 2 1.12 (1.07, 1.17) <0.001 1.28 (1.08, 1.53) 0.005
Model 3 1.03 (0.97, 1.09) 0.345 0.95 (0.75, 1.20) 0.665
Model 4 1.02 (0.96, 1.08) 0.485 0.93 (0.73, 1.18) 0.561
Total number of participants included in model 1: n = 3121 (fasting plasma glucose); n = 2920 (2 h post-load glucose); n = 3115 (HbA1c); n = 2959
(SAF); n = 2709 (ISI); and n = 2814 (HOMA-IR)
Number of prevalent depression cases in model 1: n = 138 (fasting plasma glucose); n = 113 (2 h post-load glucose); n = 139 (HbA1c); n = 131 (SAF);
n = 101 (ISI); and HOMA-IR (n = 110)
Model 1: crude
Model 2: adjusted for age, sex and educational level. Data missing, n = 60 (fasting plasma glucose)
Model 3: additionally adjusted for waist circumference, office systolic blood pressure, antihypertensive medication, total-to-HDL-cholesterol ratio, lipid-
modifying medication and history of CVD. Additional missing data, n = 128 (fasting plasma glucose)
Model 4: additionally adjusted for smoking behaviour and alcohol use. Additional missing data, n = 97 (fasting plasma glucose)
a The reciprocal was used for the ISI (1/ISI)
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cardiometabolic risk profile than participants included in
the analyses (data not shown).
Table 1 shows the general characteristics of the study popu-
lation at baseline, stratified for incident depressive symptoms.
Participants had a mean age of 59.9 ± 8.1 years and 48.8%
were women. Participants with incident depressive symptoms
had a worse cardiometabolic risk profile compared with
participants free of depressive symptoms.
In cross-sectional analyses, markers of hyperglycaemia and
insulin resistance were associated with prevalent depressive
symptoms. However, associations with insulin resistance
were attenuated after adjustment for cardiovascular and life-
style factors, in particular waist circumference (Table 2).
Associations of hyperglycaemia with incident depressive
symptoms Table 3 shows the associations of markers of
hyperglycaemia with incident depressive symptoms. Fasting
plasma glucose, 2 h post-load glucose and HbA1c levels were
associated with an increased risk for incident depressive
symptoms after full adjustment (HR 1.20 [95% CI 1.08,
1.33]; HR 1.25 [1.08, 1.44]; and HR 1.22 [1.09, 1.37] per
SD, respectively). SAF was not associated with incident
depressive symptoms (HR 0.99 [0.86, 1.13] per SD). No inter-
actions were found with regard to sex for fasting plasma
glucose (p-interaction = 0.981), 2 h post-load glucose (p-inter-
action = 0.234) and HbA1c (p-interaction = 0.686). There was
an interaction with sex for SAF (p-interaction = 0.031);
however, associations were not significant in stratified analy-
ses for men (HR 1.13 [0.94, 1.37] per SD) or women (HR 0.83
[0.67, 1.02] per SD).
Associations of insulin resistance with incident depressive
symptoms Table 3 shows the associations of insulin resistance
with incident depressive symptoms. A lower ISI and a higher
HOMA-IR were associated with an increased risk for incident
depressive symptoms after adjustment for age, sex and educa-
tional level (HR 1.21 [1.03, 1.42] and HR 1.19 [1.05, 1.34] per
SD, respectively). After additional adjustment for cardiovas-
cular risk factors, these associations were attenuated (HR 1.03
[0.86, 1.23] and HR 0.99 [0.84, 1.17] per SD, respectively).
These attenuations were mainly caused by waist circumfer-
ence (model 2 additionally adjusted for waist circumference:
HR 1.04 [0.87, 1.24] and HR 1.02 [0.87, 1.19] per SD, respec-
tively). No interaction with regard to sex was found for ISI (p-
interaction = 0.589) and HOMA-IR (p-interaction = 0.621).
Additional analyses Results of additional analyses are shown
in Table 4. Additional adjustment for type 2 diabetes, and
excluding participants with type 2 diabetes from the analyses,
did not materially change the associations. As expected, addi-
tional adjustment for type 2 diabetes attenuated the associa-
tions, but HRs remained directionally similar.
Table 3 Associations of markers of hyperglycaemia and insulin resis-
tance with incident depressive symptoms
Model Incident depressive symptoms
(PHQ-9 ≥10) HR (95% CI)
p value
Markers of hyperglycaemia
Fasting plasma glucose (per 1 SD)
Model 1 1.35 (1.25, 1.46) <0.001
Model 2 1.33 (1.22, 1.45) <0.001
Model 3 1.21 (1.09, 1.34) <0.001
Model 4 1.20 (1.08, 1.33) 0.001
2 h post-load glucose (per 1 SD)
Model 1 1.32 (1.18, 1.47) <0.001
Model 2 1.29 (1.14, 1.45) <0.001
Model 3 1.26 (1.09, 1.46) 0.002
Model 4 1.25 (1.08, 1.44) 0.003
HbA1c (per 1 SD)
Model 1 1.44 (1.32, 1.57) <0.001
Model 2 1.40 (1.27, 1.53) <0.001
Model 3 1.28 (1.15, 1.43) <0.001
Model 4 1.22 (1.09, 1.37) 0.001
SAF (per 1 SD)
Model 1 1.15 (1.02, 1.30) 0.019
Model 2 1.12 (0.99, 1.28) 0.075
Model 3 1.06 (0.93, 1.22) 0.401
Model 4 0.99 (0.86, 1.13) 0.831
Markers of insulin resistance
ISI (per SD)a
Model 1 1.22 (1.05, 1.43) 0.010
Model 2 1.21 (1.03, 1.42) 0.018
Model 3 1.03 (0.86, 1.23) 0.748
Model 4 1.03 (0.86, 1.23) 0.783
HOMA-IR (per SD)
Model 1 1.19 (1.06, 1.34) 0.003
Model 2 1.19 (1.05, 1.34) 0.006
Model 3 0.99 (0.84, 1.17) 0.962
Model 4 0.98 (0.83, 1.15) 0.766
Total number of participants included in model 1: n = 2846 (fasting plas-
ma glucose); n = 2683 (2 h post-load glucose); n = 2842 (HbA1c); n =
2710 (SAF); n = 2496 (ISI); and n = 2585 (HOMA-IR)
Number of incident depression cases in model 1: n = 265 (fasting plasma
glucose); n = 226 (2 h post-load glucose); n = 264 (HbA1c); n = 254
(SAF); n = 212 (ISI); and n = 220 (HOMA-IR)
Model 1: crude
Model 2: adjusted for age, sex and educational level. Data missing, n = 49
(fasting plasma glucose)
Model 3: additionally adjusted for waist circumference, office systolic
blood pressure, antihypertensive medication, total-to-HDL-cholesterol
ratio, lipid-modifying medication and history of CVD. Additional miss-
ing data, n = 71 (fasting plasma glucose)
Model 4: additionally adjusted for smoking behaviour and alcohol use.
Additional missing data, n = 133 (fasting plasma glucose)
a The reciprocal was used for the ISI to define it as risk factor (1/ISI)
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Table 4 Additional analyses for associations of markers of hyperglycaemia with incident depressive symptoms
Model Incident clinically relevant
depressive symptoms
(PHQ-9 ≥10) HR (95% CI)
p value
Fasting plasma glucose (per 1 SD)
Model 4 1.20 (1.08, 1.33) 0.001
Model 5: model 4 + type 2 diabetes 1.12 (0.99, 1.27) 0.085
Model 6: model 4 excl. type 2 diabetes (excluded data n = 683) 1.35 (0.81, 2.25) 0.255
Model 7: model 4 + antidepressant medication 1.20 (1.08, 1.33) 0.001
Model 8: model 4 excl. antidepressant users (missing data n = 152) 1.18 (1.05, 1.33) 0.006
Model 9: model 4 excl. baseline MDD (excluded data n = 150) 1.19 (1.06, 1.33) 0.003
Model 10: model 4 excl. lifetime MDD (excluded data n = 897) 1.06 (0.87, 1.29) 0.580
Model 11: model 4 + physical activity (missing data n = 160) 1.19 (1.07, 1.33) 0.002
Model 12: model 4 + Mediterranean diet (missing data n = 123) 1.18 (1.06, 1.32) 0.002
Model 13: model 4 replacing office SBP for 24 h SBP (missing data n = 294) 1.19 (1.06, 1.33) 0.003
Model 14: model 4 replacing waist circumference for BMI 1.21 (1.09, 1.34) <0.001
Model 15: model 4 replacing total-to-HDL-cholesterol ratio for triacylglycerols 1.17 (1.05, 1.30) 0.004
2 h post-load glucose (per 1 SD)
Model 4 1.25 (1.08, 1.44) 0.003
Model 5: model 4 + type 2 diabetes 1.16 (0.93, 1.45) 0.192
Model 6: model 4 excl. type 2 diabetes (excluded data n = 539) 1.19 (0.78, 1.83) 0.419
Model 7: model 4 + antidepressant medication 1.27 (1.10, 1.47) 0.001
Model 8: model 4 excl. antidepressant users (missing data n = 132) 1.26 (1.08, 1.47) 0.003
Model 9: model 4 excl. baseline MDD (excluded data n = 143) 1.23 (1.05, 1.44) 0.009
Model 10: model 4 excl. lifetime MDD (excluded data n = 840) 1.18 (0.94, 1.49) 0.163
Model 11: model 4 + physical activity (missing data n = 153) 1.22 (1.04, 1.42) 0.014
Model 12: model 4 + Mediterranean diet (missing data n = 116) 1.24 (1.06, 1.44) 0.006
Model 13: model 4 replacing office SBP for 24 h SBP (missing data n = 274) 1.23 (1.05, 1.44) 0.008
Model 14: model 4 replacing waist circumference for BMI 1.25 (1.08, 1.44) 0.002
Model 15: model 4 replacing total-to-HDL-cholesterol ratio for triacylglycerols 1.21 (1.04, 1.40) 0.015
HbA1c (per 1 SD)
Model 4 1.22 (1.09, 1.37) 0.001
Model 5: model 4 + type-2 diabetes 1.14 (1.00, 1.31) 0.057
Model 6: model 4 excl. type-2 diabetes (excluded data n = 684) 1.23 (0.82, 1.83) 0.318
Model 7: model 4 + antidepressant medication 1.23 (1.10, 1.38) <0.001
Model 8: model 4 excl. antidepressant users (missing data n = 152) 1.18 (1.03, 1.34) 0.017
Model 9: model 4 excl. baseline MDD (excluded data n = 150) 1.21 (1.07, 1.37) 0.003
Model 10: model 4 excl. lifetime MDD (excluded data n = 894) 1.08 (0.87, 1.33) 0.486
Model 11: model 4 + physical activity (missing data n = 160) 1.25 (1.11, 1.41) <0.001
Model 12: model 4 + Mediterranean diet (missing data n = 123) 1.20 (1.06, 1.35) 0.004
Model 13: model 4 replacing office SBP for 24 h SBP (missing data n = 294) 1.23 (1.08, 1.41) 0.002
Model 14: model 4 replacing waist circumference for BMI 1.23 (1.10, 1.38) <0.001
Model 15: model 4 replacing total-to-HDL-cholesterol ratio for triacylglycerols 1.20 (1.07, 1.35) 0.002
SAF (per 1 SD)
Model 4 0.99 (0.86, 1.13) 0.831
Model 5: model 4 + type-2 diabetes 0.94 (0.85, 1.11) 0.606
Model 6: model 4 excl. type-2 diabetes (excluded data n = 658) 0.87 (0.72, 1.05) 0.154
Model 7: model 4 + antidepressant medication 1.00 (0.87, 1.15) 0.975
Model 8: model 4 excl. antidepressant users (missing data n = 147) 1.01 (0.87, 1.18) 0.852
Model 9: model 4 excl. baseline MDD (excluded data n = 145) 1.01 (0.87, 1.17) 0.876
Model 10: model 4 excl. lifetime MDD (excluded data n = 854) 1.00 (0.81, 1.25) 0.985
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Adjustments to reduce potential misclassification of partic-
ipants with subthreshold depression did not materially change
our results. Furthermore, applying stricter rules on the follow-
up data, allowing no or a maximum of one missing follow-up
measurement for the control participants, did not materially
change our results (data not shown).
Similar strengths of the associations were found after addition-
al adjustment for physical activity or Mediterranean diet score.
Furthermore, our results were not materially changed by replac-
ing office systolic blood pressure with 24 h ambulatory systolic
blood pressure, replacing waist circumference with BMI or
replacing total-to-HDL-cholesterol ratio with triacylglycerols.
Discussion
This population-based study demonstrates that fasting plasma
glucose, 2 h post-load glucose and HbA1c were associated
with incident depressive symptoms, with an increased risk of
~20% per SD higher level of hyperglycaemia markers. These
associations were independent of demographical, cardiovas-
cular and lifestyle-related risk factors, and were similar in
women and men. The association of insulin resistance with
incident depressive symptoms was explained by cardiovascu-
lar risk factors (waist circumference). Our results suggest that
hyperglycaemia precedes the development of depression, and
may be directly involved in its aetiology.
Our finding that hyperglycaemia is associated with incident
depressive symptoms corroborates and further extends previous
evidence of an association between type 2 diabetes and incident
depression [30], and provides additional evidence that
hyperglycaemia as such may be involved in the development
of depression. This is in line with results of a large-scale cross-
sectional study that showed an association between both diag-
nosed and undiagnosed diabetes and higher prevalence of
depression [31]. Although a previous meta-analysis concluded
that hyperglycaemia is unlikely to be causally related to incident
depressive symptoms [8], this study did not investigate a linear
contribution of hyperglycaemia to the incidence of depression.
Several pathophysiological pathways may explain the
association between hyperglycaemia and incident depression.
Hyperglycaemia is associated with generalised microvascular
dysfunction [32], which may consequently lead to cerebral
small vessel disease and subsequent depression [33]. Indeed,
a recent meta-analysis showed that cerebrovascular damage
was associated with incident depression [34]. Optimising
blood glucose levels is the most effective therapy to prevent
the development of microvascular complications in type 2
diabetes, and could potentially also contribute to preventing
or slowing down the development of depressive symptoms.
Alternatively, suboptimal blood glucose levels may also iden-
tify those individuals at high risk for depression. Furthermore,
hyperglycaemia has been associated with low-grade inflam-
mation [35], which in turn has been associated with cerebro-
vascular damage [36] and incident depression as well [37]. In
support of this potential mechanism, several studies have
shown that treatment resistance to antidepressants is associat-
ed with low-grade inflammation [38] and that anti-
inflammatory therapy may be beneficial to individuals with
depression [39]. Moreover, hyperglycaemia may activate the
polyol pathway which induces oxidative stress, increases lipid
peroxidation and imbalances the generation of ROS [40].
These processes may lead to apoptosis in the brain, which
may eventually lead to depression via shrinkage of specific
brain structures (atrophy) [41]. This assumption is supported
by a stronger association between oxidative stress and depres-
sion in individuals with IGM and type 2 diabetes than in those
with NGM [42]. Furthermore, previous studies have assumed
that diabetes may increase risk of depression because of
disease burden [8]. However, disease burden alone may be
not sufficient to explain the association between
hyperglycaemia and incident depression, since 65% of the
Table 4 (continued)
Model Incident clinically relevant
depressive symptoms
(PHQ-9 ≥10) HR (95% CI)
p value
Model 11: model 4 + physical activity (missing data n = 150) 1.03 (0.89, 1.19) 0.696
Model 12: model 4 + Mediterranean diet (missing data n = 117) 1.00 (0.87, 1.16) 0.986
Model 13: model 4 replacing office SBP for 24 h SBP (missing data n = 280) 0.93 (0.81, 1.08) 0.353
Model 14: model 4 replacing waist circumference for BMI 0.99 (0.86, 1.14) 0.897
Model 15: model 4 replacing total-to-HDL-cholesterol ratio for triacylglycerols 0.98 (0.86, 1.13) 0.800
Total number of participants in model 4: n = 2714 (fasting plasma glucose); n = 2565 (2 h post-load glucose); n = 2710 (HbA1c); n = 2582 (SAF)
Incident depressive symptoms in model 4: n = 254 (fasting plasma glucose); n = 217 (2 h post-load glucose); n = 253 (HbA1c); and n = 244 (SAF)
Model 4 is adjusted for age, sex, educational level, waist circumference, office systolic blood pressure, antihypertensive medication, total-to-HDL-
cholesterol ratio, lipid-modifying medication, history of CVD, smoking behaviour and alcohol use
Excl., excluding; SBP, systolic blood pressure
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association remained after additional adjustment for type 2
diabetes. In addition, the suggestion that somatic symptoms
may explain this association is unlikely, as a previous study of
our group has shown that affective and somatic symptoms do
not differ between individuals with and individual without
type 2 diabetes [43].
We found no association between SAF and incident depres-
sive symptoms, although earlier cross-sectional analyses in a
smaller dataset (n = 866) from The Maastricht Study did show
an association between higher SAF and prevalent depression
[20]. SAF is thought to represent the accumulation of fluores-
cent AGEs in the skin, but may be a less specific measure of
hyperglycaemia, as it also measures other fluorescent proteins
in the skin and does not reflect non-fluorescent AGEs [44].
Nevertheless, there are currently no other prospective studies
available that have assessed this association. Therefore, this
finding warrants replication in other prospective population-
based studies in order to draw firm conclusions.
We found that the association of insulin resistance with inci-
dent depression was explained by CVD risk factors, in particu-
lar central obesity. This is in contrast with results of the
Whitehall II Study, the Caerphilly Study and the Pittsburgh
Healthy Heart Project, which did not show an association
between insulin resistance and incident depression after adjust-
ment for age only [15, 16]. Furthermore, our results contrast
with the results of the Health in Men Study, which did show an
association between higher insulin resistance and incident
depression after adjustment for cardiovascular risk factors
including central obesity [14]. However, the Health in Men
Study only included older men aged 70–93 years, which
hinders direct comparison with our somewhat younger popula-
tion. There are several explanations for the attenuation of the
association between insulin resistance and incident depressive
symptoms after adjustment for central obesity. First, central
obesity may be on the causal pathway from insulin resistance
to depression, which might have resulted in overadjustment.
Second, as performing clamps is not feasible in large-scale
studies, we used surrogate markers of insulin resistance.
These markers moderately reflect hepatic and muscular insulin
resistance, which may or may not coincide with cerebral insulin
resistance [45]. Consequently, we cannot fully exclude the
possibility that cerebral insulin resistance is involved in the
development of depression. Third, insulin resistance is less
precisely measured than hyperglycaemia. The use of surrogate
markers of insulin resistance may have created more noise in
the data as compared with the direct markers of
hyperglycaemia. Alternatively, hyperglycaemia may be one of
the mechanisms linking insulin resistance to depression.
Obesity is associated with the development of insulin resis-
tance, but only individuals who lack sufficient insulin secretion
to match the degree of insulin resistance will develop type 2
diabetes [46].
The association of hyperglycaemia with an increased risk
of depressive symptoms has important clinical implications.
First, professionals in diabetes care should be aware of the
prevalence of depression, and use diagnostic skills to recog-
nise and treat depression properly. For this, specific guidelines
to identify and manage depressive symptoms in diabetes care
have been developed [47]. In addition to these guidelines, it is
important to distinguish between need for treatment and a high
score on a questionnaire [48]. Since depression in individuals
with type 2 diabetes is often persistent [6], and is related to
suboptimal blood glucose levels [3], early recognition and
treatment of depressive symptoms could have a favourable
effect on the outcome of both diseases [49]. Considering the
high comorbidity of depression and type 2 diabetes, integrated
care approaches that treat these conditions jointly need to be
implemented in diabetes care.
Strengths of our study include its large sample size and
population-based longitudinal design; the oversampling of indi-
viduals with type 2 diabetes which results in more variability
within the high ranges of hyperglycaemia; the annual assessment
of the PHQ-9 to assess depressive symptoms over a 4 year peri-
od; the comparable incidence rate of depression to other
population-based studies; the use of multiple continuous markers
of hyperglycaemia; the extensive assessment of potential
confounders; and the execution of several sensitivity analyses.
This study has some limitations. First, there could have
been selection and/or attrition bias, which is inherent to
prospective population-based studies; individuals with more
severe depressive symptoms or with greater comorbidity may
have been more likely not to participate or to withdraw, which
may have led to an underestimation of the observed associa-
tions. Second, the study population was relatively well treated
with regard to glucose metabolism, which may mean that the
effects of fasting plasma glucose, 2 h post-load glucose and
HbA1c on incident depression were suppressed. Estimates of
post-load glucose, ISI and HOMA-IR, did not include insulin
users, which may have led to an underestimation of the
observed findings in more severe type 2 diabetes. Third, the
population was mainly of white ethnicity and aged 40–
75 years, which should be considered when extrapolating
these findings to other populations. Fourth, we measured
depressive symptoms with the PHQ-9 questionnaire. High
scores on this questionnaire are suggestive for depressive
symptoms, but do not necessarily equate with MDD.
Finally, because follow-up data were only available for
depression data, we could not rule reverse causality; there




In conclusion, we showed that higher levels of
hyperglycaemia were associated with incident depressive
symptoms in a population-based setting, independent of major
demographical, cardiovascular and lifestyle risk factors. The
association of insulin resistance with incident depressive
symptoms was dependent on cardiovascular risk factors, in
particular, central obesity. These findings establish a temporal
relation between hyperglycaemia and incident depressive
symptoms, supporting the concept that hyperglycaemia itself
is involved in the aetiology of depression, and thus may
provide a potential target for the prevention of depression in
individuals with and without type 2 diabetes.
Acknowledgements The researchers are indebted to the participants for their
willingness to participate in the study. Some of the data were presented as an
abstract at the Psychosocial Aspects of Diabetes (PSAD) meeting and the
Annual Dutch Diabetes Research Meeting in 2019.
Data availability The data of this study derive from The Maastricht
Study, but restrictions apply to the availability of these data, which were
used under license for the current study. Data are, however, available
from the authors upon reasonable request and with permission of The
Maastricht Study management team.
Funding This study was supported by the European Regional
Development Fund via OP-Zuid, the Province of Limburg, the Dutch
Ministry of Economic Affairs (grant 31O.041), Stichting De
Weijerhorst (Maastricht, the Netherlands), the Pearl String Initiative
Diabetes (Amsterdam, the Netherlands), the Cardiovascular Center
(CVC, Maastricht, the Netherlands), CARIM School for Cardiovascular
Diseases (Maastricht, the Netherlands), CAPHRI Care and Public Health
Research Institute (Maastricht, the Netherlands), NUTRIM School for
Nutrition and Translational Research in Metabolism (Maastricht, the
Netherlands), Stichting Annadal (Maastricht, the Netherlands), Health
Foundation Limburg (Maastricht, the Netherlands) and Perimed
(Järfalla, Sweden), and by unrestricted grants from Janssen-Cilag B.V.
(Tilburg, the Netherlands), Novo Nordisk Farma B.V. (Alphen aan den
Rijn, the Netherlands) and Sanofi Netherlands B.V. (Gouda, the
Netherlands). The study sponsors/funders were not involved in the design
of the study; the collection, analysis and interpretation of data; writing the
report; and did not impose any restrictions regarding the publication of the
report.
Authors’ relationships and activities The authors declare that there are no
relationships or activities that might bias, or be perceived to bias, their work.
Contribution statement AFJG, SK, RM, CGS, AO, SJPME, PCD, CDAS,
NCS, RMAH, CJHvdK, AW, AK, FRJV and MTS were involved in the
design or conduct of the study, the preparation of the manuscript and the
decision to submit it for publication, and all verify the accuracy and complete-
ness of the data analyses. AFJG, SK and MTS analysed data and drafted the
article. AFJG, SK, RM, CGS, AO, SJPME, PCD, CDAS, NCS, RMAH,
CJHvdK, AW, AK, FRJV and MTS commented on the drafts and contrib-
uted to writing. AFJG, SK, RM, CGS, AO, SJPME, PCD, CDAS, NCS,
RMAH, CJHvdK, AW, AK, FRJV and MTS approved the final version.
AFJG is the guarantor of this work and, as such, had full access to all the data
in the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Roy T, Lloyd CE (2012) Epidemiology of depression and diabetes:
a systematic review. J Affect Disord 142:S8–S21. https://doi.org/
10.1016/S0165-0327(12)70004-6
2. SchramMT, Baan CA, Pouwer F (2009) Depression and quality of life
in patients with diabetes: a systematic review from the European
Depression in Diabetes (EDID) Research Consortium. Curr Diabetes
Rev 5(2):112–119. https://doi.org/10.2174/157339909788166828
3. Pouwer F, Nefs G, Nouwen A (2013) Adverse effects of depression
on glycemic control and health outcomes in people with diabetes: a
review. Endocrinol Metab Clin N Am 42(3):529–544. https://doi.
org/10.1016/j.ecl.2013.05.002
4. Katon W, Lyles CR, Parker MM, Karter AJ, Huang ES, Whitmer
RA (2012) Association of depression with increased risk of demen-
tia in patients with type 2 diabetes: the Diabetes and Aging Study.
Arch Gen Psychiatry 69(4):410–417. https://doi.org/10.1001/
archgenpsychiatry.2011.154
5. Molosankwe I, Patel A, Gagliardino JJ, Knapp M, McDaid D
(2012) Economic aspects of the association between diabetes and
depression: a systematic review. J Affect Disord 142:S42–S55.
https://doi.org/10.1016/S0165-0327(12)70008-3
6. Nefs G, Pouwer F, Denollet J, Pop V (2012) The course of depres-
sive symptoms in primary care patients with type 2 diabetes: results
from the Diabetes, Depression, Type D Personality Zuidoost-
Brabant (DiaDDZoB) Study. Diabetologia 55(3):608–616. https://
doi.org/10.1007/s00125-011-2411-2
7. van Sloten T, SchramM (2018) Understanding depression in type 2
diabetes: a biological approach in observational studies. F1000Res
7:F1000 Faculty Rev-1283. https: / /doi.org/10.12688/
f1000research.13898.1
8. Tong A, Wang X, Li F, Xu F, Li Q, Zhang F (2016) Risk of
depressive symptoms associated with impaired glucose metabo-
lism, newly diagnosed diabetes, and previously diagnosed diabetes:
a meta-analysis of prospective cohort studies. Acta Diabetol 53(4):
589–598. https://doi.org/10.1007/s00592-016-0845-1
9. Pieper L, Dirmaier J, Klotsche J et al (2011) Longitudinale
Assoziationen zwischen depressiven Symptomen und Typ-2-




10. Icks A, Albers B, Haastert B et al (2013) Risk for high depressive
symptoms in diagnosed and previously undetected diabetes: 5-year
follow-up results of the Heinz Nixdorf Recall Study. PLoS One
8(2):e56300. https://doi.org/10.1371/journal.pone.0056300
11. Okumiya K, Fujisawa M, Sakamoto R et al (2015) Effect of early
diagnosis and lifestyle modification on depressive symptoms in
community-dwelling elderly adults with glucose intolerance: 5-
year longitudinal study. J Am Geriatr Soc 63(2):393–395. https://
doi.org/10.1111/jgs.13269
2326 Diabetologia (2020) 63:2315–2328
12. Demakakos P, Zaninotto P, Nouwen A (2014) Is the association
between depressive symptoms and glucose metabolism bidirection-
al? Evidence from the English Longitudinal Study of Ageing.
Psychosom Med 76(7):555–561. https://doi.org/10.1097/psy.
0000000000000082
13. Golden SH, Lazo M, Carnethon M et al (2008) Examining a bidirec-
tional association between depressive symptoms and diabetes. JAMA
299(23):2751–2759. https://doi.org/10.1001/jama.299.23.2751
14. Ford AH, Flicker L, Hankey GJ et al (2015) Insulin resistance and
depressive symptoms in older men: the Health in Men Study. Am J
Geriatr Psychiatry 23(8):872–880. https://doi.org/10.1016/j.jagp.
2014.10.010
15. Lawlor DA, Ben-Shlomo Y, Ebrahim S et al (2005) Insulin resis-
tance and depressive symptoms in middle aged men: findings from
the Caerphilly prospective cohort study. BMJ 330(7493):705–706.
https://doi.org/10.1136/bmj.38377.616921.F7
16. Akbaraly TN, Kumari M, Head J et al (2013) Glycemia, insulin
resistance, insulin secretion, and risk of depressive symptoms in
middle age. Diabetes Care 36(4):928–934. https://doi.org/10.
2337/dc12-0239
17. Khambaty T, Stewart JC, Muldoon MF, Kamarck TW (2014)
Depressive symptom clusters as predictors of 6-year increases in
insulin resistance: data from the Pittsburgh Healthy Heart Project.
Psychosom Med 76(5):363–369. https://doi.org/10.1097/psy.
0000000000000063
18. Schram MT, Sep SJ, van der Kallen CJ et al (2014) The Maastricht
Study: an extensive phenotyping study on determinants of type 2
diabetes, its complications and its comorbidities. Eur J Epidemiol
29(6):439–451. https://doi.org/10.1007/s10654-014-9889-0
19. WorldHealth Organization (2006) Definition and diagnosis of diabetes
mellitus and intermediate hyperglycaemia: report of a WHO/IDF
consultation. World Health Organization, Geneva, Switzerland
20. van Dooren FE, Pouwer F, Schalkwijk CG et al (2017) Advanced
glycation end product (AGE) accumulation in the skin is associated
with depression: the Maastricht Study. Depress Anxiety 34(1):59–
67. https://doi.org/10.1002/da.22527
21. Singh B, SaxenaA (2010) Surrogate markers of insulin resistance: a
review. World J Diabetes 1(2):36–47. https://doi.org/10.4239/wjd.
v1.i2.36
22. DeFronzo RA, Matsuda M (2010) Reduced time points to calculate
the composite index. Diabetes Care 33(7):e93–e93. https://doi.org/
10.2337/dc10-0646
23. MatsudaM,DeFronzo RA (1999) Insulin sensitivity indices obtain-
ed from oral glucose tolerance testing: comparison with the
euglycemic insulin clamp. Diabetes Care 22(9):1462–1470.
https://doi.org/10.2337/diacare.22.9.1462
24. The Oxford Centre for Diabetes, Endocrinology and Metabolism
Diabetes Trials Unit. HOMA2 Calculator. Available from https://
www.dtu.ox.ac.uk/homacalculator/. Accessed 7 Feb 2019
25. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of
HOMA modeling. Diabetes Care 27(6):1487–1495. https://doi.
org/10.2337/diacare.27.6.1487
26. Kroenke K, Spitzer R, Williams J (2001) The PHQ-9: validity of a
brief depression severity measure. Gen Intern Med 16:606–613.
https://doi.org/10.1046/j.1525-1497.2001.016009606.x
27. Bell CC (1994) DSM-IV: diagnostic and statistical manual of
mental disorders. JAMA 272(10):828–829. https://doi.org/10.
1001/jama.1994.03520100096046
28. Pettersson A, BostromKB,Gustavsson P, Ekselius L (2015)Which
instruments to support diagnosis of depression have sufficient accu-
racy? A systematic review. Nord J Psychiatry 69(7):497–508.
https://doi.org/10.3109/08039488.2015.1008568
29. Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The Mini-
International Neuropsychiatric Interview (MINI): the development
and validation of a structured diagnostic psychiatric interview for
DSM-IV and ICD-10. J Clin Psychiatry 59:22–33
30. Rotella F, Mannucci E (2013) Diabetes mellitus as a risk factor for
depression. A meta-analysis of longitudinal studies. Diabetes Res
Clin Pract 99(2):98–104. https://doi.org/10.1016/j.diabres.2012.11.022
31. Meurs M, Roest AM, Wolffenbuttel BH, Stolk RP, de Jonge P,
Rosmalen JG (2016) Association of depressive and anxiety disor-
ders with diagnosed versus undiagnosed diabetes: an epidemiolog-
ical study of 90,686 participants. Psychosom Med 78(2):233–241.
https://doi.org/10.1097/psy.0000000000000255
32. Stehouwer CD (2018) Microvascular dysfunction and hyperglyce-
mia: a vicious cycle with widespread consequences. Diabetes 67(9):
1729–1741. https://doi.org/10.2337/dbi17-0044
33. Wardlaw JM, Smith EE, Biessels GJ et al (2013) Neuroimaging
standards for research into small vessel disease and its contribution
to ageing and neurodegeneration. Lancet Neurol 12(8):822–838.
https://doi.org/10.1016/s1474-4422(13)70124-8
34. van Agtmaal MJ, Houben AJ, Pouwer F, Stehouwer CD, SchramMT
(2017) Association of microvascular dysfunction with late-life depres-
sion: a systematic review and meta-analysis. JAMA Psychiatry 74(7):
729–739. https://doi.org/10.1001/jamapsychiatry.2017.0984
35. Wang X, Bao W, Liu J et al (2013) Inflammatory markers and risk
of type 2 diabetes: a systematic review and meta-analysis. Diabetes
Care 36(1):166–175. https://doi.org/10.2337/dc12-0702
36. Leonard BE (2007) Inflammation, depression and dementia: are
they connected? Neurochem Res 32(10):1749–1756. https://doi.
org/10.1007/s11064-007-9385-y
37. Pasco JA, Nicholson GC,Williams LJ et al (2010) Association of high-
sensitivity C-reactive protein with de novo major depression. Br J
Psychiatry 197(5):372–377. https://doi.org/10.1192/bjp.bp.109.076430
38. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives
A, Cleare AJ (2015) Inflammation and clinical response to treatment in
depression: ameta-analysis. Eur Neuropsychopharmacol 25(10):1532–
1543. https://doi.org/10.1016/j.euroneuro.2015.06.007
39. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM
(2018) Antidepressant activity of anti-cytokine treatment: a system-
atic review and meta-analysis of clinical trials of chronic inflamma-
tory conditions. Mol Psychiatry 23(2):335–343. https://doi.org/10.
1038/mp.2016.167
40. Sima AA, Kamiya H, Li ZG (2004) Insulin, C-peptide, hypergly-
cemia, and central nervous system complications in diabetes. Eur J
Pharmacol 490(1–3):187–197
41. McKernan DP, Dinan TG, Cryan JF (2009) “Killing the Blues”: a
role for cellular suicide (apoptosis) in depression and the antide-
pressant response? Prog Neurobiol 88(4):246–263. https://doi.org/
10.1016/j.pneurobio.2009.04.006
42. Van Sloten T, Schram MT, Adriaanse M et al (2014) Endothelial
dysfunction is associated with a greater depressive symptom score
in a general elderly population: the Hoorn Study. Psychol Med
44(7):1403–1416. https://doi.org/10.1017/S0033291713002043
43. Janssen EP, Köhler S, Stehouwer CD et al (2016) The Patient
Health Questionnaire-9 as a screening tool for depression in indi-
viduals with type 2 diabetes mellitus: the Maastricht Study. J Am
Geriatr Soc 64(11). https://doi.org/10.1111/jgs.14388
44. MeerwaldtR,GraaffR,OomenPetal(2004)Simplenon-invasiveassess-
ment of advanced glycation endproduct accumulation. Diabetologia
47(7):1324–1330. https://doi.org/10.1007/s00125-004-1451-2
45. Banks WA, Owen JB, Erickson MA (2012) Insulin in the brain:
there and back again. Pharmacol Ther 136(1):82–93. https://doi.
org/10.1016/j.pharmthera.2012.07.006
46. Al-Goblan AS, Al-Alfi MA, Khan MZ (2014) Mechanism linking
diabetes mellitus and obesity. Diabetes Metab Syndr Obes 7:587–591
47. Young-Hyman D, De Groot M, Hill-Briggs F, Gonzalez JS, Hood
K, Peyrot M (2016) Psychosocial care for people with diabetes: a
position statement of the American Diabetes Association. Diabetes
Care 39(12):2126–2140. https://doi.org/10.2337/dc16-2053
48. Snoek FJ, Hermanns N, deWitM et al (2018) Comment onYoung-
Hyman et al. Psychosocial care for people with diabetes: a position
2327Diabetologia (2020) 63:2315–2328
statement of the American Diabetes Association. Diabetes Care
2016;39:2126–2140. Diabetes Care 41(3):e31–e32. https://doi.
org/10.2337/dc17-1102
49. Schmitt A, Reimer A, Ehrmann D, Kulzer B, Haak T, Hermanns N
(2017) Reduction of depressive symptoms predicts improved
glycaemic control: secondary results from the DIAMOS study. J
Diabetes Complicat 31(11):1608–1613. https://doi.org/10.1016/j.
jdiacomp.2017.08.004
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
2328 Diabetologia (2020) 63:2315–2328
